IV LBH589 + Oral LBH589 + trastuzumab + paclitaxel
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
HER-2 Positive Breast Cancer
Conditions
HER-2 Positive Breast Cancer, Metastatic Breast Cancer
Trial Timeline
Dec 1, 2008 → —
NCT ID
NCT00788931About IV LBH589 + Oral LBH589 + trastuzumab + paclitaxel
IV LBH589 + Oral LBH589 + trastuzumab + paclitaxel is a phase 1 stage product being developed by Novartis for HER-2 Positive Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00788931. Target conditions include HER-2 Positive Breast Cancer, Metastatic Breast Cancer.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00788931 | Phase 1 | Completed |
Competing Products
11 competing products in HER-2 Positive Breast Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Trastuzumab + Capecitabine + Cisplatin | Celltrion | Phase 2 | 52 |
| eribulin + carboplatin + trastuzumab | Eisai | Phase 1/2 | 41 |
| Apatinib and S-1 | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| V930 | Merck | Phase 1 | 33 |
| Everolimus + Vinorelbine + Trastuzumab | Novartis | Phase 2 | 52 |
| T-DM1 | Roche | Phase 2 | 52 |
| Trastuzumab + Paclitaxel + Epirubicin + Carboplatin | Roche | Phase 2 | 52 |
| palbociclib + trastuzumab + pertuzumab + letrozole + Anastrozole + Exemestane + Fulvestrant | Pfizer | Phase 3 | 76 |
| Zumsemetinib + Capecitabine + Zoledronic acid + Denosumab | United Therapeutics | Phase 1/2 | 38 |
| Alisertib + Endocrine therapy | Puma Biotechnology | Phase 2 | 44 |
| Margetuximab + Trastuzumab + Physician's choice of chemotherapy. | MacroGenics | Phase 3 | 69 |